Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 62INDUSTRY 36OTHER_GOV 3UNKNOWN 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 265Leukemia 183Carcinoma, Non-Small-Cell Lung 168Lymphoma 159Lung Neoplasms 148Prostatic Neoplasms 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Ovarian Neoplasms 117Colorectal Neoplasms 115Sarcoma 108Central Nervous System Neoplasms 107Head and Neck Neoplasms 98Leukemia, Myeloid, Acute 95Multiple Myeloma 93Squamous Cell Carcinoma of Head and Neck 83Rectal Neoplasms 77Colonic Neoplasms 71Uterine Cervical Neoplasms 65Neoplasm Metastasis 65Neuroblastoma 64Carcinoma, Ovarian Epithelial 64Brain Neoplasms 64Neoplasms 63Fallopian Tube Neoplasms 62Lymphoma, Large B-Cell, Diffuse 61Astrocytoma 59Melanoma 58Leukemia, Lymphocytic, Chronic, B-Cell 56Burkitt Lymphoma 56Hodgkin Disease 55

Interventions

pegfilgrastim 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Breast Diseases × Clear all
NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NSABP Foundation Inc

Phase 3 Completed
1,613 enrolled
Breast

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡